DailySand tracks weight loss drugs across AI, semiconductor infrastructure, capital markets, and critical minerals supply chains. Below are curated source items and daily digests where weight loss drugs appears in today's cross-sector intelligence briefing.
3 items across 3 digests
A weight loss drug maker's stock fell 23% after new safety data raised investor concerns despite the experimental drug meeting primary efficacy targets. Adverse side effect profiles can eliminate commercial viability and investor returns even when clinical efficacy is demonstrated.
Read original →The FDA approved Eli Lilly's GLP-1 pill Foundayo, entering the oral weight loss drug market three months after Novo Nordisk's oral Wegovy launch. This creates competition in the rapidly growing weight loss pharmaceutical market.
Read original →Zealand's stock plummeted 35% after their joint drug with Roche showed disappointing 10.7% weight loss results in mid-stage trials. CEO downplays competitive comparisons amid intense competition in the weight-loss drug market.
Read original →
DailySand